Biologic treatment, male patients, and pregnancy
Linda Stein Gold, MD
December 1, 2008
Question:
Are there any concerns about placing a male patient who is trying to father a child on a biologic such as efalizumab? Answer:
I do not know of any studies that have examined spermatogenesis. We do have some data on pregnancy in women. Alefacept, etanercept, adalimumab, and infliximab are all pregnancy category “B”; efalizumab is pregnancy category “C.” There are pregnancy registries for women who have been exposed to etanercept and adalimumab in early gestation and followed for 1 year postpartum. The numbers are still very small, but at this point no consistent pattern of abnormalities has been noted among etanercept-exposed or adalimumab-exposed pregnancies.
 Ask the Expert Home
|
 |
|
